| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2012-07-09 | Camurus (Sweden) Cangene (Canada) | episil® (mixture of soy phospholipid (lecithin) and glycerol dioleate) | management and relief of pain associated with oral lesions, including oral mucositis (OM), which results from cancer therapy and other causes | commercialisation |
Cancer - Oncology - CNS diseases | Commercialisation agreement |
| 2012-07-09 | Merck KGaA, Merck Serono (Germany) PDS Biotechnology (USA) | Versamune™ nanotechnology platform | licensing | Cancer - Oncology | Licensing agreement | |
| 2012-07-09 | Boehringer Ingelheim (Germany) Harvard’s Office of Technology Development (USA) | novel signaling pathways and drug targets in oncology, cardiometabolic, fibrotic and infectious diseases | oncology, cardiometabolic, fibrotic and infectious diseases. | R&D |
Cancer - Oncology - Cardiovascular diseases - Metabolic diseases - Infectious diseases | R&D agreement |
| 2012-07-09 | Bayer (Germany) Horizon Discovery (UK) | preclinical cell line models for oncology research | collaboration |
Cancer - Oncology | Services contract | |
| 2012-07-09 | Prokarium (UK) Emergent BioSolutions (USA) | live Salmonella-based typhoid vaccine Typhella™ and its genetic technology spi-VEC™ | product acquisition |
Infectious diseases | Product acquisition | |
| 2012-07-07 | Novo Nordisk (Denmark) Benaroya Research Institute (USA) | rheumatoid arthritis, inflammatory bowel disease, lupus | R&D |
Autoimmune diseases – Digestive diseases - Inflammatory diseases - Rheumatic diseases | R&D agreement | |
| 2012-07-06 | Cancer Research Technology (UK) ADC Therapeutics (Switzerland) | antibody drug conjugates (ADCs) using CRT antibodies and peptides, and ADC Therapeutics ‘warhead’ and linker chemistries. | undisclosed cancers | development |
Cancer - Oncology | Development agreement |
| 2012-07-06 | Wilex (Germany) Prometheus (USA) | Rencarex® | commercialisation |
Cancer - Oncology | Commercialisation agreement | |
| 2012-07-05 | MDX Health (Belgium) Merck KGaA, Merck Serono (Germany) | PredictMDx for BrainTM (MGMT assay) | brain cancer (glioblastoma) | development |
Cancer - Oncology | Development agreement |
| 2012-07-05 | Prosonix (UK) Imperial College London (UK) | engineered Multi-component Particles (MCPs™) as respiratory medicines. Excipient-free, drug-only MCPs engineered by Prosonix that will be evaluated in the project include Inhaled corticosteroids (ICS) with long-acting beta-agonist (LABA), and LABAs with long-acting muscarinic antagonists (LAMA) | chronic obstructive pulmonary disease (COPD), asthma | R&D |
Respiratory diseases - Inflammatory diseases - Allergic diseases | R&D agreement |
| 2012-07-05 | Medunik (Canada) Orphan Europe, part of Recordati Group (Italy) | orphan drugs | acute hepatic porphyria, patent ductus arteriosus, vitamin E deficiency in chronic cholestasis | distribution |
Rare diseass | Distribution agreement |
| 2012-07-05 | Calixar (France) Synthelis (France) | membrane protein services | collaboration |
Services contract | ||
| 2012-07-03 | Ferring Pharmaceuticals (Switzerland) Albireo (Sweden) | elobixibat | chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C) | licensing |
Digestive diseases - Inflammatory diseases | Licensing agreement |
| 2012-07-03 | Vivalis (France) Merck Animal Health - Merck&Co (USA) | EB66® cell line | licensing |
Veterinary medicine | Licensing agreement | |
| 2012-07-02 | AstraZeneca (UK) Cellworks (UK) | novel combination therapies for the treatment of drug-sensitive and resistant tuberculosis | tuberculosis | R&D |
Infectious diseases | R&D agreement |
| 2012-06-26 | Medivir (Sweden) Swedish University of Agricultural Sciences (Sweden) | new drugs for bacterial infections | bacterial infections | R&D |
Infectious diseases | R&D agreement |
| 2012-06-26 | VTT Technical Research Centre of Finland (Finland) GE Healthcare (USA) | novel biomarkers to predict Alzheimer's disease | Alzheimer's disease | R&D |
Neurodegenerative diseases | R&D agreement |
| 2012-06-25 | Quotient Clinical (UK) Capsugel (USA) | services and technologies for development clinical assessment of lipid-based formulations | collaboration |
Services contract | ||
| 2012-06-20 | CellCentric (UK) ZoBio (The Netherlands) | lead compounds against CellCentric’s portfolio of epigenetic therapeutic drug targets | cancer | development |
Cancer - Oncology | Development agreement |
| 2012-06-20 | Genfit (France) Imabiotech (France) | drug discovery services | Services contract |
